Phase 4 N=62 ATAREAL (Antihistamine Treatment for Allergic Rhinitis in Real Life)
Rhinitis, Allergic, Perennial
Primary: Mean Weekly Total 4 Symptom Score (T4SS) During the Treatment Period — 2.89; 3.15 units on a scale — p==0.667
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=251 Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan
Acromegaly
Primary: Number of Participants With Treatment-Related Adverse Events — 89; 20 Participants
Phase 1 N=64 A Study of LY3113593 in Healthy Participants and Participants With Chronic Kidney Disease Treated With Hemodialysis
Kidney Failure, Chronic
Primary: Number of Participants With One or More Serious Adverse Event (s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0…
N/A N=45 PilAm Go4Health Weight Loss Program to Prevent Heart Disease
Type2 Diabetes
Primary: Feasibility for Participant Enrollment and Retention — 22; 23 percentage of participants retained
Phase 2 N=365 Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection
Hepatitis C, Chronic
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After End of Treatment (EOT) (SVR12) — 98.9; 97.8 Percentage of Participants
Phase 1 N=26 A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy Subjects
Hypertension, Pulmonary
Primary: Maximum Observed Concentration (Cmax) of Ambrisentan and Tadalafil in FDC (Ambrisentan 10 mg + Tadalafil 40 mg) and Montherapies (Ambrisentan 10 mg & Tadalafil 40 mg)…
Phase 4 N=128 A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer
Colorectal Neoplasms
Primary: Association Between Neutrophil to Lymphocyte Ratio (NLR) [NLR ≤5 Versus NLR >5] and Progression-Free Survival (PFS) as Assessed by Hazard Ratio — 1.4 hazard ratio…
Phase 1 N=48 Ascending Multiple-Doses of Erenumab (AMG 334) in Healthy Adults and in Migraine Patients
Migraine
Primary: Number of Participants With Adverse Events — 5; 6; 6; 6 Participants
Phase 1 N=14 A Study of IMC-TR1 in Participants With Advanced Solid Tumors
Neoplasms · Tumor
Primary: Number of Participants With Dose-Limiting Toxicities (DLTs) — 2; 0; 2 Participants
N/A N=100 Associated Joint Pain With Controlled Ankle Movement (CAM) Walker Boot Wear
Pain · Ankle Injuries
Primary: The Presence and Severity of Secondary Site Pain — 31 Participants
N/A N=60 Manual Lymphatic Drainage Following Total Knee Arthroplasty Surgery
Knee Arthroplasty, Total
Primary: Bioimpedance Percentage Difference Healthy/Operated — 1.8; 0.2; 12.9; 13.7 percentage difference between limbs — p=0.51
Phase 3 N=750 Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A
Infections, Streptococcal
Primary: Number of Subjects Reported With Core Fever (Rectal Temperature) Greater Than or Equal to (≥) the Cut-off — 64; 14; 100; 16 Participants
N/A N=1,881 Impact of Diet on Functional Gastrointestinal Symptoms
Gastrointestinal Disorder, Functional
Primary: Most Common Triggers for Food-related GI Symptoms (Top 5) — 881; 494; 469; 460 Participants
Phase 4 N=20 The Effect of Corticotrophin (ACTH) in Combination With Methotrexate in Newly Diagnosed Rheumatoid Arthritis Patients
Rheumatoid Arthritis
Primary: Change From Baseline in Clinical Disease Activity Index (CDAI) Score — 0; 0; 0; 0 Participants
N/A N=190 Comparison of SomnaPatch With Polysomnography in Sleep Disordered Breathing
Obstructive Sleep Apnea · Central Sleep Apnea · Mixed Sleep Apnea
Primary: Agreement Between Polysomnography (PSG) and SomnaPatch in Detecting Patients Apnea-Hypopnea Index (AHI) — 87.1 percentage of device agreements